BMO Capital lowered the firm’s price target on AMN Healthcare (AMN) to $33 from $38 and keeps an Outperform rating on the shares. The company reported a better-than-expected quarter largely due to labor disruption upside as Nurse and Allied posted its first sequential growth in three years, but the guidance for Q1 was mixed with revenues slightly above consensus, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
- AMN Healthcare Services: Signs of Turnaround and Stability Ahead
- AMN Healthcare price target lowered to $33 from $34 at Citizens JMP
- AMN Healthcare’s Mixed Earnings Call Highlights Challenges and Successes
- AMN Healthcare price target lowered to $26 from $30 at BofA
- AMN Healthcare price target lowered to $40 from $47 at Truist